Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients

Clinical Neurophysiology

Volumn 113, Issue 8, 2002, Pages 1241-1248

  Nobili, Flavio ^a   Vitali, Paolo ^a   Canfora, Michela ^b   Girtler, Nicola ^a   De Leo, Caterina ^a   Mariani, Giuliano ^c   Pupi, Alberto ^b   Rodriguez, Guido ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Alzheimer's disease; Brain SPECT; Donepezil; Mini mental state examination score; rCBF; Statistical parametric mapping

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BLOOD FLOW; BRAIN PERFUSION; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DIAGNOSTIC VALUE; DRUG EFFECT; DRUG SCREENING; FEMALE; FRONTAL LOBE; HUMAN; LEFT HEMISPHERE; LONG TERM EXPOSURE; MALE; MINI MENTAL STATE EXAMINATION; OCCIPITAL CORTEX; OCCIPITAL LOBE; PARIETAL LOBE; PRIORITY JOURNAL; SCINTILLATION CAMERA; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL PARAMETERS; TEMPORAL CORTEX; TEMPORAL LOBE;

AGED; ALZHEIMER DISEASE; BRAIN; BRAIN MAPPING; CHOLINESTERASE INHIBITORS; FEMALE; HUMANS; INDANS; MALE; NEUROPSYCHOLOGICAL TESTS; PIPERIDINES; REGIONAL BLOOD FLOW; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0036340381     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-2457(02)00110-4     Document Type: Article

References (46)

1. Quantitative analysis of PET and MRI data in normal ageing and Alzheimer's disease: Atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators
2. A method for attenuation correction in radionuclide computed tomography
3. Correlations of topographical EEG features with clinical severity in mild and moderate dementia of Alzheimer type
4. Cholinergic markers in elderly patients with early signs of Alzheimer disease
5. Open-label multicenter, phase 3 extension study of the safety and efficacy of Donepezil in patients with Alzheimer's disease
6. Donepezil: A review of its use in Alzheimer's disease
7. A 24-week, randomised, double-blind study of donepezil in moderate to severe Alzheimer's disease
8. 'Mini Mental State': A practical method for grading the cognitive state of patients for clinician
9. Comparing functional (PET) images: The assessment of significant changes
10. Spatial registration and normalization of images
11. The development of ASPECT, an annular single crystal brain camera for high efficiency SPECT
12. Present and future of Alzheimer therapy
13. Cholinesterase inhibitors stabilize Alzheimer's disease
14. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease?
15. Cholinesterase inhibitors for Alzheimer's disease
16. Emission tomography contribution to clinical neurology
17. Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: Validation of anatomic standardisation for atrophied brains
18. Procedure guidelines for brain perfusion SPECT using Technetium-99m radiopharmaceuticals
19. Cognition-enhancing drugs increase stimulated hippocampal theta rhythm amplitude in the urethane-anesthetized rat
20. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT
21. Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex
22. Brain energy metabolism
23. Cerebral blood flow and metabolic abnormalities in Alzheimer's disease
24. Treatment of Alzheimer's disease
25. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
26. The cholinergic deficit in Alzheimer's disease: Impact on cognition, behaviour and function
27. Clinical brain radionuclide imaging studies
28. And CERAD investigators. The consortium to establish a registry for Alzheimer's disease
29. Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease
30. Functional studies of new drugs for the treatment of Alzheimer's disease
31. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases
32. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease
33. The effects of Donepezil on the P300 auditory and visual cognitive evoked potentials of patients with Alzheimer's disease
34. The ability of THA treatment to increase cortical alpha waves is related to apolipoprotein E genotype of Alzheimer disease patients
35. Quantitative electroencephalograhy and regional cerebral blood flow: Discriminant analysis between Alzheimer's patients and healthy controls
36. 99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer's disease: A correlative study
37. Hippocampal perfusion in mild Alzheimer's disease
38. The efficacy and safety of Donepezil in patients with Alzheimer's disease: Results of a US multicenter, randomized, double-blind, placebo-controlled trial
39. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
40. Cholinergic neural regulation of regional cerebral blood flow
41. Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET
42. Changes in the rCBF images of patients Alzheimer's disease receiving Donepezil therapy
43. P300 in Alzheimer's disease: Relationships to dementia severity and glucose metabolism
44. Age-related impairment of coupling mechanism between neuronal activation and functional cerebral blood flow response was restored by cholinesterase inhibition: PET study with microdialysis in the awake monkey brain
45. Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: A PET study in conscious monkeys
46. Imaging brain cholinergic activity with positron emission tomography: Its role in the evaluation of cholinergic treatments in Alzheimer's dementia